Drug-induced nephrotoxicity or drug-induced kidney disease (DIKD) is primarily recognized as a significant contributor to kidney disease including acute kidney injury (AKI) and chronic kidney disease (CKD). Drug-induced nephrotoxicity is often go unrecognized, particularly in the setting of short drug exposures, which leads challenges in assessing the incidence, severity and long-term consequences of drug-induced kidney disease. The mechanisms for drug-induced nephrotoxicity include changes in glomerular hemodynamics, tubular cell toxicity, inflammation, crystal nephropathy, rhabdomyolysis, and thrombotic microangiopathy.
Drug-induced nephrotoxicity tends to be more common among certain patients and in specific clinical situations. Some patient-related risk factors for drug-induced nephrotoxicity are observed among population older than 60 years, underlying renal insufficiency, volume depletion, diabetes, heart failure, and sepsis. Thus, the general preventive measures for drug-induced nephrotoxicity treatment, is adoption of non-nephrotoxic drugs. This drug-induced nephrotoxicity treatment corrects the risk factors of renal dysfunction and cardiovascular disease. Additionally, drug-induced nephrotoxicity successful prevention requires knowledge of pathogenic mechanisms of renal injury, patient-related risk factors, drug-related risk factors, and preventive measures, coupled with vigilance and early intervention.
Drug-induced Nephrotoxicity Treatment Market: Drivers and Restraints
The growing prevalence of kidney disorders is expected to be the major factor driving the growth of the drug-induced nephrotoxicity treatment market over the forecast period. Increasing geriatric who are more prone drugs toxicity is also one of the key factor which is driving the drug-induced nephrotoxicity treatment. For instance, more than 661,000 American have kidney failure and in 2013 more than 47,000 American died from kidney disease (source: National Institute of Diabetes and Kidney Diseases). Furthermore, rise in usage of biomarkers by large scale pharmaceuticals manufacturing companies to overcome increasing failure rates for drugs in clinical trial phase II and III is considered to be the major factor which is driving the drug-induced nephrotoxicity treatment market. Moreover, increasing drug development cost is also fueling the growth for global drug-induced nephrotoxicity treatment market.
Besides, increasing initiatives by National Institutes of Health (NIH), National Institute of Diabetes and Kidney Diseases (NIDDK), and CDC also lead to increase in research and development of biomarker for the drug-induced nephrotoxicity treatment. Drug-induced nephrotoxicity treatment market is expected to show a high growth rate due to increased clinical trial for drug development with the support of government organization. Increasing prevalence of acute kidney injury (AKI) and chronic kidney disease is the major driving factor of drug-induced nephrotoxicity treatment market.
However, high cost of validation and high capital investment required for the application, discovery and development of biomarkers are some of the factors restraining the growth for global drug-induced nephrotoxicity treatment market. Less awareness regarding drug-induced nephrotoxicity treatment is the major factor expected to restrain drug-induced nephrotoxicity treatment market.
Drug-induced Nephrotoxicity Treatment Market: Segmentation
Tentatively, the global drug-induced nephrotoxicity treatment market can be segmented on the basis of biomarker and end users, and geography.
Based on biomarkers, the global drug-induced nephrotoxicity treatment market is segmented as:
- Immunoglobulin G
- Cystatin C Retinol binding protein
- Kidney Injury Molecule-1 (KIM-1)
- Neutrophil gelatinase-associated lipocalin (NGAL)
Based on end users, the global drug-induced nephrotoxicity treatment market is segmented as:
- Pharmaceutical and Biotechnology Companies
- Academic Institutes
- Research Organizations
Drug-induced Nephrotoxicity Treatment Market: Overview
The global market for drug-induced nephrotoxicity treatment is expected to witness moderate growth over the forecast period. Since drug-induced nephrotoxicity is observed as common problem in clinical medicine and the incidence of drug-related acute kidney injury (AKI) is predicted as high as 60%. Hence the high demand of biomarkers is expected for drug-induced nephrotoxicity treatment. Furthermore, it has been observed that, the increase in use of biomarkers for treatment, due to increase in prevalence of various diseases caused by toxicity. Besides, government initiatives and FDA support for biomarkers development and increasing demand of personalized medicine are some of the factors propelling the growth for global drug-induced nephrotoxicity treatment market.
Drug-induced Nephrotoxicity Treatment Market: Regional Outlook
Geographically, the global drug-induced nephrotoxicity treatment market is segmented into viz. North America, Latin America, Europe, •CIS & Russia, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to be the dominant market in the global drug-induced nephrotoxicity treatment market owing to the highly supportive government initiatives. Europe is expected to have the second largest share in the global drug-induced nephrotoxicity treatment market throughout the forecast period owing to growing awareness related to the major health issues. The drug-induced nephrotoxicity treatment market in the Asia Pacific excluding Japan is expected to grow at a significant CAGR due to the increasing healthcare expenditure and growing healthcare facilities.
Drug-induced Nephrotoxicity Treatment Market: Key Players
Examples of some of the key players operating in the global drug-induced nephrotoxicity treatment market are Roche Diagnostic Limited, Siemens Healthcare, Abbott Laboratories Inc., Thermo Fisher Scientific, Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., Aushon BioSystem Inc., Epistem Ltd, G.E. Healthcare Inc., and Affymetrix, Inc. Companies are conducting research for the development of new drug-induced nephrotoxicity treatment biomarkers which expected to provide the high growth opportunity for drug-induced nephrotoxicity treatment market.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico, Brazil, Argentina, Peru, Chile, Rest of LATAM)
- Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX, Eastern Europe, Rest of Europe)
- CIS & Russia
- Asia Pacific Excluding Japan ( Greater China, India, South Korea, ASEAN Countries, Rest of APEJ)
- Middle East and Africa (GCC Countries, Turkey, Iran, Israel, S. Africa, Rest of MEA)
- Detailed overview of parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
- Must-have information for market players to sustain and enhance their market footprint.
Fact.MR offers custom research services that help clients to get specific research solutions